First Biomarker for Idiopathic Pulmonary Fibrosis Accepted by FDA, Promising More Efficient Treatments The PROLIFIC consortium's Risk Score has been accepted into the FDA Biomarker Qualification Program, paving the way for better treatments for idiopathic pulmonary fibrosis.

First Biomarker for Idiopathic Pulmonary Fibrosis Accepted by FDA, Promising More Efficient Treatments #United_States #Chicago #Pulmonary_Fibrosis #PROLIFIC_Risk_Score #FDA_CDER